{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:53:51Z","timestamp":1793811231511,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003809"],"award-info":[{"award-number":["82003809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222157"],"award-info":[{"award-number":["7222157"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.isci.2022.104991","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T12:28:32Z","timestamp":1661171312000},"page":"104991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Icaritin inhibits CDK2 expression and activity to interfere with tumor progression"],"prefix":"10.1016","volume":"25","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2022.104991_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.coph.2013.03.012","article-title":"Tumour selective targeting of cell cycle kinases for cancer treatment","volume":"13","author":"Aarts","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.isci.2022.104991_bib2","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1021\/acschembio.5b00398","article-title":"Type II inhibitors targeting CDK2","volume":"10","author":"Alexander","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.isci.2022.104991_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into CDK regulators: novel opportunities for cancer therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.isci.2022.104991_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2017.06.028","article-title":"Structural evidence of quercetin multi-target bioactivity: a reverse virtual screening strategy","volume":"106","author":"Carvalho","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.isci.2022.104991_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of Disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2022.104991_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12013-014-0499-y","article-title":"Icaritin sensitizes human glioblastoma cells to TRAIL-induced apoptosis","volume":"72","author":"Han","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.isci.2022.104991_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nm1729","article-title":"Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart","volume":"14","author":"Hauck","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2022.104991_bib8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.4161\/cc.6.8.4122","article-title":"CDK2 and FOXO1: a fork in the road for cell fate decisions","volume":"6","author":"Huang","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2022.104991_bib9","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1242\/jcs.001222","article-title":"Dynamic FoxO transcription factors","volume":"120","author":"Huang","year":"2007","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.isci.2022.104991_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1126\/science.1130512","article-title":"CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage","volume":"314","author":"Huang","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.isci.2022.104991_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fchem.2018.00138","article-title":"Reverse screening methods to search for the protein targets of chemopreventive compounds","volume":"6","author":"Huang","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.isci.2022.104991_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1073\/pnas.0900121106","article-title":"Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation","volume":"107","author":"Hydbring","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2022.104991_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tibs.2018.12.007","article-title":"Interconnection between metabolism and cell cycle in cancer","volume":"44","author":"Icard","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.isci.2022.104991_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6605479","article-title":"Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells","volume":"102","author":"Johnson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2022.104991_bib15","first-page":"354","article-title":"Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81. Biochimica et biophysica acta","volume":"1865","author":"Jorda","year":"2018","journal-title":"Molecular cell research"},{"key":"10.1016\/j.isci.2022.104991_bib16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1535-7163.MCT-17-1108","article-title":"Engaging anaphase catastrophe mechanisms to eradicate aneuploid cancers","volume":"17","author":"Kawakami","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2022.104991_bib17","first-page":"64","article-title":"Development of anti-viral agents using molecular modeling and virtual screening techniques","volume":"11","author":"Kirchmair","year":"2011","journal-title":"Infect. Disord.: Drug Targets"},{"key":"10.1016\/j.isci.2022.104991_bib18","doi-asserted-by":"crossref","first-page":"eabl8876","DOI":"10.1126\/science.abl8876","article-title":"p53 directs leader cell behavior, migration, and clearance during epithelial repair","volume":"375","author":"Kozyrska","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2022.104991_bib19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","article-title":"Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition","volume":"81","author":"Kumarasamy","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2022.104991_bib20","doi-asserted-by":"crossref","first-page":"165715","DOI":"10.1016\/j.bbadis.2020.165715","article-title":"Cell cycle regulators in cancer cell metabolism","volume":"1866","author":"Leal-Esteban","year":"2020","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.isci.2022.104991_bib21","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3892\/or.2015.3891","article-title":"Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2","volume":"33","author":"Li","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.isci.2022.104991_bib22","doi-asserted-by":"crossref","first-page":"e81657","DOI":"10.1371\/journal.pone.0081657","article-title":"Icaritin inhibits JAK\/STAT3 signaling and growth of renal cell carcinoma","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2022.104991_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm761","article-title":"PKB\/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest","volume":"8","author":"Liang","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2022.104991_bib24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/eji.202048905","article-title":"Icaritin inhibits PD-L1 expression by targeting protein IkappaB kinase alpha","volume":"51","author":"Mo","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2022.104991_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2022.104991_bib26","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1128\/MCB.24.24.10542-10557.2004","article-title":"Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2","volume":"24","author":"Pierson-Mullany","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2022.104991_bib27","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/0008-5472.CAN-19-3663","article-title":"p27 as a transcriptional regulator: new roles in development and cancer","volume":"80","author":"Razavipour","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2022.104991_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2022.104991_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2174\/1389201017666160709200208","article-title":"Reverse pharmacognosy and reverse pharmacology; two closely related approaches for drug discovery development","volume":"17","author":"Saeidnia","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.isci.2022.104991_bib30","doi-asserted-by":"crossref","first-page":"126637","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015-2019)","volume":"29","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.isci.2022.104991_bib31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/nm759","article-title":"PKB\/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization","volume":"8","author":"Shin","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2022.104991_bib32","first-page":"177","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.isci.2022.104991_bib33","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.isci.2022.104991_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","article-title":"The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit","volume":"155","author":"Spencer","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.isci.2022.104991_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2022.104991_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcb.2011.10.004","article-title":"Multiple degradation pathways regulate versatile CIP\/KIP CDK inhibitors","volume":"22","author":"Starostina","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.isci.2022.104991_bib37","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.3892\/mmr.2014.3007","article-title":"Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells","volume":"11","author":"Sun","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.isci.2022.104991_bib38","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.isci.2022.104991_bib39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","article-title":"Targeting CDK2 in cancer: challenges and opportunities for therapy","volume":"25","author":"Tadesse","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.isci.2022.104991_bib40","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.isci.2022.104991_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy","volume":"17","author":"Wang","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.isci.2022.104991_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/aps.2013.178","article-title":"Icaritin suppresses the proliferation of human osteosarcoma cells in\u00a0vitro by increasing apoptosis and decreasing MMP expression","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2022.104991_bib43","first-page":"4860268","article-title":"Icaritin: a novel natural candidate for hematological malignancies therapy","volume":"2019","author":"Yang","year":"2019","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.isci.2022.104991_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/fon-2017-0561","article-title":"Identification of CDK2 as a novel target in treatment of prostate cancer","volume":"14","author":"Yin","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2022.104991_bib45","first-page":"4288","article-title":"MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression","volume":"24","author":"Yu","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.isci.2022.104991_bib46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/ijc.29548","article-title":"Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm","volume":"137","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2022.104991_bib47","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/hep.29326","article-title":"Hepatic stimulator substance resists hepatic ischemia\/reperfusion injury by regulating Drp1 translocation and activation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2022.104991_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11596-014-1305-1","article-title":"Anticancer effect of icaritin on human lung cancer cells through inducing S phase cell cycle arrest and apoptosis","volume":"34","author":"Zheng","year":"2014","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.isci.2022.104991_bib49","doi-asserted-by":"crossref","first-page":"740557","DOI":"10.3389\/fonc.2021.740557","article-title":"Icaritin-induced FAM99A affects GLUT1-mediated glycolysis via regulating the JAK2\/STAT3 pathway in hepatocellular carcinoma","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222012639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222012639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:07:41Z","timestamp":1762880861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004222012639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2589004222012639"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2022.104991","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Icaritin inhibits CDK2 expression and activity to interfere with tumor progression","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2022.104991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"104991"}}